Figure 3 | Scientific Reports

Figure 3

From: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Figure 3

LB100 enhances daunorubicin cytotoxicity to sAML in vitro. (A–D) LB100 significantly enhanced the cytolytic activity of daunorubicin in SKM-1 cells, and in three primary sAML patient samples. Statistically significant differences are marked by an asterisk (*P < 0.05; **P < 0.01, ***P ≤ 0.001).

Back to article page